Otsuka and Lundbeck plan to roll out the product in August. "Psychiatric diseases remain a challenging therapeutic area where many people are unsatisfied with their treatments," Tatsuo Higuchi, Otsuka's President, said in a statement. "Today's approval of Rexulti is another example of Otsuka and Lundbeck's commitment to bringing new therapeutic alternatives to the mental health community." The FDA approval marks a critical win for Otsuka, which had fought to the bitter end to keep generic versions of the original Abilify off the market.